Literature DB >> 12490307

Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells.

Thomas W Grunt1.   

Abstract

Chemoresistance of ovarian cancer can be overcome by co-administration of retinoids, albeit clinical proof of this hypothesis is pending. Moreover, growth factor/c-erbB signaling is crucial for ovarian tumor growth/chemosensitivity. Retinoids and c-erbB modulators therefore represent promising drugs for ovarian cancer. We demonstrate that c-erbB-1 (RG-14620, AG1517) and c-erbB-2 selective tyrphostins (AG825, AG879), and all-trans and 9-cis retinoic acid inhibit ovarian cancer cell proliferation (HOC-7, OVCAR-3). Unlike retinoids, AG1517 and AG879 induce apoptosis. The antiproliferative activity of AG1517 is enhanced by all-trans retinoic acid suggesting that c-erbB and retinoid pathways interact. Thus, these agents cooperate during ovarian cancer cell growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490307     DOI: 10.1016/s0304-3835(02)00512-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

Review 1.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

2.  Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.

Authors:  Chung-Pu Wu; Sung-Han Hsiao; Megumi Murakami; Ming-Jie Lu; Yan-Qing Li; Chia-Hung Hsieh; Suresh V Ambudkar; Yu-Shan Wu
Journal:  Cancer Lett       Date:  2017-09-08       Impact factor: 8.679

3.  A cell-based high-throughput screen identifies tyrphostin AG 879 as an inhibitor of animal cell phospholipid and fatty acid biosynthesis.

Authors:  Raphael A Zoeller; Kathleen Geoghegan-Barek
Journal:  Biochem Biophys Rep       Date:  2019-03-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.